Cancer drug dasatinib takes aim at hidden HIV in small trial
NCT ID NCT07342491
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether dasatinib, a drug used for leukemia, can reduce the hidden HIV reservoir in people whose virus is already suppressed by antiretroviral therapy (ART). Fourteen adults on ART for at least 4 years will be randomly assigned to take dasatinib or a placebo daily for 12 weeks, with 24 weeks of follow-up. The goal is to see if the drug safely lowers the amount of dormant HIV in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dasatinib (a cancer drug taken as a pill)
What this could lead to
If it works, this could point toward a way to shrink the hidden HIV reservoir, potentially helping people manage HIV without needing lifelong medication.
What could go wrong
This is a very early, small Phase 1 trial with only 14 people. Dasatinib may not reduce the reservoir at all, and it can cause side effects like low blood counts or fluid retention.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
1401, University of Washington Positive Research CRS
RECRUITINGSeattle, Washington, 98104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
2501, Case CRS
NOT_YET_RECRUITINGCleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern University CRS (Site # 2701)
NOT_YET_RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••